These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 9269901

  • 1. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
    Okamoto M, Oyasu R.
    Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
    [Abstract] [Full Text] [Related]

  • 2. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
    Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S, Yoshino G.
    Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Guo Y, Kyprianou N.
    Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
    [Abstract] [Full Text] [Related]

  • 4. Effect of epidermal growth factor/transforming growth factor alpha and transforming growth factor beta 1 on growth in vitro of rat urinary bladder carcinoma cells.
    Kawamata H, Azuma M, Kameyama S, Nan L, Oyasu R.
    Cell Growth Differ; 1992 Nov; 3(11):819-25. PubMed ID: 1467309
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y, Kyprianou N.
    Cancer Res; 1999 Mar 15; 59(6):1366-71. PubMed ID: 10096572
    [Abstract] [Full Text] [Related]

  • 7. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
    Deng X, Bellis S, Yan Z, Friedman E.
    Cell Growth Differ; 1999 Jan 15; 10(1):11-8. PubMed ID: 9950213
    [Abstract] [Full Text] [Related]

  • 8. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
    Clin Cancer Res; 2005 Jun 15; 11(12):4512-20. PubMed ID: 15958637
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M.
    Clin Cancer Res; 2001 Sep 15; 7(9):2931-40. PubMed ID: 11555612
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV, Gama P, Wen X, Demopoulos R, Munger JS, Carcangiu ML, Reiss M, Gold LI.
    Cancer Res; 2002 May 15; 62(10):2778-90. PubMed ID: 12019154
    [Abstract] [Full Text] [Related]

  • 14. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
    Masi L, Malentacchi C, Campanacci D, Franchi A.
    Virchows Arch; 2002 May 15; 440(5):491-7. PubMed ID: 12021923
    [Abstract] [Full Text] [Related]

  • 15. Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
    Mincione G, Di Marcantonio MC, Artese L, Vianale G, Piccirelli A, Piccirilli M, Perrotti V, Rubini C, Piattelli A, Muraro R.
    Int J Oncol; 2008 Feb 15; 32(2):323-31. PubMed ID: 18202754
    [Abstract] [Full Text] [Related]

  • 16. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B, Groth S, Sebens Müerköster S, Sipos B, Schäfer H, Kalthoff H, Fändrich F, Ungefroren H.
    Oncogene; 2007 Jul 19; 26(33):4850-62. PubMed ID: 17297450
    [Abstract] [Full Text] [Related]

  • 17. Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
    Hattori K, Okamoto M, Oyasu R.
    Carcinogenesis; 1997 Oct 19; 18(10):1867-70. PubMed ID: 9363992
    [Abstract] [Full Text] [Related]

  • 18. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma.
    Zhang G, Cao Y, Xu Y, See WA.
    Urol Oncol; 2005 Oct 19; 23(6):413-8. PubMed ID: 16301119
    [Abstract] [Full Text] [Related]

  • 19. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
    Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP, Danielpour D, Wakefield LM.
    Cancer Res; 1999 Oct 01; 59(19):4834-42. PubMed ID: 10519393
    [Abstract] [Full Text] [Related]

  • 20. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
    Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK, Zborowska E, Brattain MG.
    J Cell Physiol; 1998 Aug 01; 176(2):424-34. PubMed ID: 9648930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.